CD274 and neoplasm: Generally speaking, PD-L1 levels expressed by tumor cells are associated with a response to PD-1/PD-L1 inhibitor therapies that are widely used to treat patients with non-hematologic and hematologic malignancies, including lung cancers, melanoma, and lymphomas [12,13].